Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and health care issues, forecast today that chemokine modulators are likely to generate blockbuster sales because of their use in multiple disease drug markets. By far the greatest potential lies in the development of chemokine modulators for the treatment of inflammatory and immune-mediated diseases such as rheumatoid arthritis, asthma, and multiple sclerosis. Within these disease areas, the most important advantage chemokine modulators are likely to offer is their selectivity and specificity in therapy. The HIV drug market is also likely to benefit greatly from chemokine modulators, potentially generating $1-2 billion for this market by 2012, according to a new Pathways and Processes report entitled Chemokine Modulators: Emerging Therapeutic Opportunities.
(Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION)
"Inhibitors of the chemokine receptors CCR5 and CXCR4 are the most promising emerging class of antiretrovirals (ARVs), and are likely to provide the next 'breakthrough' advance in HIV therapy," said John Lebbos, M.D., analyst at Decision Resources, "Schering-Plough, Pfizer, Merck, and Progenics are all competing for first-to-market chemokine modulators for the HIV market."
Chemokines are a family of structurally related glycoproteins that are involved in the recruitment and activation of leukocytes. Chemokines play a central role in several physiological and pathological processes including inflammation, viral infection, and cancer. In an increasingly competitive industry, biopharmaceutical manufacturers are under mounting pressure to market an annual array of blockbuster drugs. In this quest for novel drugs and drug targets, the chemokine system provides vast commercial potential. Future therapeutic opportunities for chemokine modulators are vast and include applications in inflammation, autoimmune diseases, infectious diseases, and cancer.
Chemokine Modulators: Emerging Therapeutic Applications is the third report from Pathways and Processes, a new advisory service that focuses on cellular and molecular pathways. The reports provide insight into cutting-edge developments relating to drug targets with the potential to significantly change treatment practice and impact multiple pharmaceutical markets.
About Decision Resources
Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.dresources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
CONTACT: Elizabeth Marshall Decision Resources 781-296-2563 firstname.lastname@example.org
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,
Web site: http://www.dresources.com/